Corey Reuteman-Fowler, Ph.D.

Alia Therapeutics is present at ASGCT Baltimore, the 27th Annual Meeting of American Society of Gene & Cell Therapy.  Meet Antonio Casini, Alia co-founder and CTO, on Wednesday 8th, presenting poster “ A novel mutation-independent CRISPR-based gene therapy to treat autosomal dominant retinitis pigmentosa”. https://lnkd.in/drdhej43 , POSTER SESSION B6 - Ophthalmic and Auditory Diseases 654   Alia Therapeutics has a vision to revolutionize medicine by curing genetic diseases at their roots. Our thesis: The diversity and complexity of human genetic diseases demands a customized approach and relying on a limited set of enzymes wouldn’t suffice. Alia’s versatile portfolio of novel CRISPR systems expands the range of targetable genomics sites and increases the precision of genetic modifications, bringing gene editing to the next level of specificity and safety, which is required for therapeutic applications. Learn more at https://lnkd.in/dDVgwXVE #genetherapy, #geneediting, #asgct, #baltimore, #aliatherapeutics

34

Glad to see more commitment from Bristol Myers Squibb Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries PRINCETON, NJ / ACCESSWIRE / May 22, 2024 / Bristol Myers Squibb (NYSE:BMY) today announced ASPIRE (Accessibility, Sustainability, Patient-centric, Impact, Responsibility and Equity), a 10-year strategy to advance access to our innovative treatments and help patients in low- and middle-income countries (LMICs) gain access to potentially life-saving medicines. This strategy supports the company's commitment to reach more than 200,000 patients in LMICs by 2033 with its innovative treatments. "Access to potentially life-saving innovative medicines is very limited in some parts of the world, leaving patients with few treatment options for serious diseases like cancer," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. "Bristol Myers Squibb believes patients who can benefit from our medicines should have access to them. Our ASPIRE strategy is an important step toward accelerating and expanding patient access to these much-needed treatments." As part of ASPIRE, Bristol Myers Squibb (BMS) is developing tailored strategies to increase affordability and availability of its medicines in LMICs. Our work to help ensure patients who need our potentially life-saving medicines can access them begins by ensuring that 100 percent of our marketed products are supported by access plans. Today we have defined access pathways for every country in which our medicines may be available to patients. In low- and middle-income countries, to help improve the affordability of our medicines, we have introduced local brands of many of our innovative medicines to address affordability issues, expand access, and help reduce the time lag between the availability of our medicines in higher-income countries and lower-income countries. In 2023, BMS filed a total of 11 local brands of which five received regulatory approvals. BMS local brands are making an impact in countries like Thailand, which has the highest prevalence of beta thalassemia, by providing treatment options like Rojusna™ to help combat this widespread disease. BMS is also making its medicines available where we don't have a commercial presence through the Direct Import and the Direct-to-Institution pathways. Through the Direct Import pathway, BMS is providing access to 12 medicines in more than 80 LMICs, using tiered pricing commensurate with affordability. The Direct-to-Institution (DTI) pathway is a scalable and sustainable channel that provides safe, broad, timelier access to BMS' innovative medicines to multiple patients through collaboration with local institutions. The company's initial DTI efforts are in five LMICs in East Africa and Pakistan and West Africa https://lnkd.in/gR42JzGj

20

Learn more about how our data and platform are making a difference in patients with cancer!

5

LinkedIn Post: New Insights on Aging: Major Biological Shifts in Your 40s and 60s! Time doesn’t just pass—it reshapes us in profound ways. Stanford Medicine’s latest research (http://med.stanford.edu) uncovers two critical periods of rapid molecular and microbial change around the ages of 44 and 60. These shifts could be the reason why you notice sudden changes in your health, metabolism, or even how you feel daily. Key Findings: • Dramatic shifts in thousands of molecules and microbes occur in our 40s and 60s. • These changes impact crucial areas like cardiovascular health, immune function, and metabolism. • This research highlights the importance of proactive health management, especially as we approach these pivotal ages. It’s never too early—or too late—to take charge of your health. Adjusting your lifestyle in your 40s and 60s could be key to aging gracefully and staying healthy longer. #Aging #HealthResearch #Biology #StanfordMedicine #Longevity #Health

27

2 Comments